On a January day in 2026, a Beijing biopharmaceutical company announced that China had given conditional approval to Libevitug, an antibody meant to shield liver cells from a virus that can only enter where hepatitis B has already taken hold. It is a small mechanism with a long history: the receptor it blocks was identified more than a decade ago, and the lab work behind it traces back through years of patient trials and public funding. For the millions who carry hepatitis D alongside hepatitis B, and who have had few options and little testing, the approval opens a door, though the evidence b
China Approves Libevitug, First Antibody Treatment for Hepatitis D, a Severe Viral Liver Disease With Few Options
HDV-HBV co-infection drives faster progression to cirrhosis, liver cancer and liver-related death; WHO estimates about 12 million people are infected worldwide.
A drug can't help people who haven't been diagnosed.
Mark
Why is this approval a big deal beyond one new drug?
Mimi
Because in China there was nothing approved for hepatitis D. With over 75 million people living with chronic hepatitis B, even a small share co-infected is a large group, and many were never tested.
Mark
How does the drug actually work?
Mimi
Hepatitis D borrows hepatitis B's envelope and enters liver cells through a receptor called NTCP. The antibody binds the PreS1 region and blocks that doorway.
Luke
Before we get carried away, where do the efficacy numbers come from?
Mimi
The company's announcement. A 44.1% combined response at Week 48, 60% virological response, 70% ALT normalization.
Luke
So that's one source, and it's a Phase IIb, open-label trial. Open-label means patients and doctors knew who got the drug. The release doesn't give the size of the trial or what the control arm was.
Mark
And the approval is conditional?
Mimi
Yes, which generally signals more evidence is expected. The release doesn't spell out the conditions.
Luke
Right, and it doesn't say price, availability or when patients can get it. Those are unknown.
Mark
What would show whether this changes anything?
Mimi
Testing rates. The WHO recommends testing all HBsAg-positive people, but the release says testing in China is low. A drug can't help people who haven't been diagnosed.
Luke
Agreed. And the claim that it lowers cancer risk is Professor Niu's anticipation, not a demonstrated result.
The Pulse
- China's regulator has conditionally approved Libevitug, the first hepatitis D treatment in the country, for adults with or without compensated cirrhosis.
- Hepatitis D rides piggyback on hepatitis B, and co-infection can speed a patient toward cirrhosis, liver cancer and death, yet testing rates remain low.
- The drug's 44.1% combined response rate at Week 48 comes from the company's own announcement, with no independent review yet attached.
- Clinicians and officials are looking toward China's 2030 goal of ending viral hepatitis as a public health problem, and the question is whether patients will be found and treated in time.
- Because the approval is conditional, the next phase of real-world uptake and testing will decide whether the promise holds.
On a January day in 2026, a Beijing biopharmaceutical company announced that China had given conditional approval to Libevitug, an antibody meant to shield liver cells from a virus that can only enter where hepatitis B has already taken hold. It is a small mechanism with a long history: the receptor it blocks was identified more than a decade ago, and the lab work behind it traces back through years of patient trials and public funding. For the millions who carry hepatitis D alongside hepatitis B, and who have had few options and little testing, the approval opens a door, though the evidence behind it still comes largely from the company itself and the wider world has yet to show what it will do.
On January 27, 2026, Huahui Health, a Beijing biopharmaceutical firm, announced that China's National Medical Products Administration had granted conditional approval to Libevitug, an injectable antibody for chronic hepatitis D. The company says it is the first hepatitis D treatment approved in China and the first antibody therapy of its kind for viral hepatitis.
Hepatitis D cannot survive on its own. It borrows the envelope proteins of hepatitis B and enters liver cells through the same receptor, NTCP, so it only infects people who already carry hepatitis B. Libevitug targets the shared PreS1 domain, aiming to block the virus at the door and prevent reinfection.
The stakes are high. Co-infection is widely described as the most severe form of chronic viral hepatitis, often doubling the risk of cirrhosis, cancer, transplant and death. The WHO estimates about 12 million people worldwide have hepatitis D, and China alone has more than 75 million people living with chronic hepatitis B. Testing has been scarce, and until now patients there had almost no approved medicine.
The efficacy figures come from a randomized Phase IIb trial presented in 2025. At Week 48, 44.1% of patients met the combined response measure, with 60% virological response and 70% ALT normalization. These numbers are the company's own, and no independent assessment accompanies them.
The drug's roots run back to 2012, when a Beijing team led by Dr. Li Wenhui identified NTCP as the entry point for these viruses. Development moved through public funding and clinical trials, earning breakthrough designations in China and the United States.
Because the approval is conditional, its meaning will be settled later. The real test is how many patients are tested, how many are treated, and whether the trial results hold outside the trial.
On January 27, 2026, Huahui Health, a Beijing biopharmaceutical company, announced that China's National Medical Products Administration had granted conditional approval to Libevitug, an injectable antibody for chronic hepatitis D virus infection. The approval covers adults with or without compensated cirrhosis. According to the company, it is the first treatment for hepatitis D approved in China and the first antibody therapy of its kind for viral hepatitis.
Hepatitis D is an unusual virus. It cannot complete its life cycle on its own and relies on the envelope proteins of the hepatitis B virus, so it infects only people who already carry hepatitis B. Both viruses enter liver cells through the same receptor, a protein called NTCP. Libevitug is a human monoclonal antibody aimed at the PreS1 domain of the large envelope protein shared by the two viruses. By blocking the contact between that domain and NTCP, it is meant to keep the viruses out of liver cells and prevent reinfection.
The stakes are considerable. The World Health Organization and the European Association for the Study of the Liver both describe hepatitis D and B co-infection as the most severe form of chronic viral hepatitis, because of its rapid progression toward cirrhosis, liver cancer and liver-related death. Per the release, co-infection accounts for roughly one in six cirrhosis cases and one in five liver cancer cases among people with hepatitis B worldwide, and it often doubles the risk of cirrhosis, cancer, transplantation and death compared with hepatitis B alone. The WHO estimates that about 12 million people are infected with hepatitis D, nearly 5% of those with chronic hepatitis B.
China's share of the problem is large. The release says more than 75 million people there live with chronic hepatitis B. Few therapies, limited clinical awareness and low testing rates have left hepatitis D patients without options. The WHO's 2024 guidelines recommend testing for anti-HDV antibodies in everyone who is HBsAg positive. The company adds that until now, apart from a drug approved in Europe, no medicine for chronic hepatitis D had been approved in either China or the United States.
The efficacy data come from study HH003-204, a multicenter, randomized, controlled, open-label Phase IIb trial presented as a late-breaker at the 2025 annual meeting of the American Association for the Study of Liver Diseases. Huahui says Libevitug beat the control group on primary and secondary endpoints, including combined response, virological response, normalization of the liver enzyme ALT, and improvement in liver stiffness. At Week 48, the combined response rate was 44.1%, the hepatitis D virological response rate was 60%, and the ALT normalization rate was 70%, with a sustained improvement in liver stiffness. The company also reports favorable tolerability and a satisfactory safety profile. These figures are the company's own; the announcement does not include independent assessment.
Professor Niu Junqi of the First Hospital of Jilin University, principal investigator of the trial, called the efficacy outstanding, particularly in patients with cirrhosis from hepatitis B and D. He tied the drug to China's Action Plan for the Prevention and Control of Viral Hepatitis (2025-2030) and its goal of eliminating viral hepatitis as a public health problem by 2030.
The science behind the drug goes back more than a decade. In 2012, a team at the National Institute of Biological Sciences, Beijing, led by Dr. Li Wenhui, the scientific founder of Huahui, identified NTCP as the receptor for hepatitis B and D infection. Dr. Li has received the Baruch S. Blumberg Prize, the Future Science Prize and the Distinguished Award in Hepatitis B Research. In 2015, Dr. Sui Jianhua, an antibody engineer and Huahui co-founder, worked with Li's team to develop the lead molecule. Clinical development began in 2018, and early work was supported by China's 13th Five-Year Plan major new-drug program. The drug won Breakthrough Therapy Designation from China's drug evaluation center in 2023 and from the U.S. FDA in 2024.
Chief executive Dr. Chen Bin said the approval fulfills the company's aim of building a translational and clinical development platform, and noted a pipeline of eight core candidates spanning hepatitis D and B, cancer and other liver diseases. Because the approval is conditional, what follows matters: how many patients get tested, how many are treated, and whether the trial results hold up in wider use.
Notable Quotes
Libevitug demonstrates outstanding clinical efficacy and significantly improves liver stiffness, with particularly remarkable efficacy in patients with HBV/HDV-related cirrhosis.— Professor Niu Junqi, principal investigator, First Hospital of Jilin University
Libevitug is the first monoclonal antibody approved in this field, treating the most severe and progressive form of chronic viral hepatitis.— Dr. Sui Jianhua, co-founder, Huahui Health (paraphrased)
Want the full story?
Read the original at The Manila Times ↗
Health & Medicine